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Abstract
Background: Prospective studies have consistently reported lower colorectal cancer risks associated with higher intakes of
total dairy products, total milk and dietary calcium. However, less is known about whether the inverse associations vary for
individual dairy products with differing fat contents.
Materials and Methods: In the European Prospective Investigation into Cancer and Nutrition (EPIC), we investigated the
associations between intakes of total milk and milk subtypes (whole-fat, semi-skimmed and skimmed), yoghurt, cheese, and
dietary calcium with colorectal cancer risk amongst 477,122 men and women. Dietary questionnaires were administered at
baseline. Multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional
hazards models, adjusted for relevant confounding variables.
Results: During the mean 11 years of follow-up, 4,513 incident cases of colorectal cancer occurred. After multivariable
adjustments, total milk consumption was inversely associated with colorectal cancer risk (HR per 200 g/day 0.93, 95% CI:
0.89–0.98). Similar inverse associations were observed for whole-fat (HR per 200 g/day 0.90, 95% CI: 0.82–0.99) and skimmed
milk (HR per 200 g/day 0.90, 95% CI: 0.79–1.02) in the multivariable models. Inverse associations were observed for cheese
and yoghurt in the categorical models; although in the linear models, these associations were non-significant. Dietary
calcium was inversely associated with colorectal cancer risk (HR per 200 mg/day 0.95, 95% CI: 0.91–0.99); this association
was limited to dairy sources of calcium only (HR per 200 mg/day 0.95, 95% CI: 0.91–0.99), with no association observed for
non-dairy calcium sources (HR per 200 mg/day 1.00, 95% CI: 0.81–1.24).
Conclusions: Our results strengthen the evidence for a possible protective role of dairy products on colorectal cancer risk.
The inverse associations we observed did not differ by the fat content of the dairy products considered.
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Introduction
Colorectal cancer is the third most common cancer worldwide,
with over 1.2 million new diagnoses estimated to have occurred in
2008 [1]. Variation in international incidence rates [2,3] coupled
with findings from migrant studies [4,5] suggests that colorectal
cancer etiology is influenced by modifiable lifestyle factors, such as
diet. In the recent WCRF/AICR Continuous Update Project,
alcoholic drinks and red and processed meat were judged to be
‘‘convincing’’ factors associated with increased colorectal cancer
risk; whilst foods containing dietary fibre were similarly judged but
associated with reduced risk [6]. For total dairy products, an
updated meta-analysis (the WCRF Continuous Update Project)
recently reported a 17% lower colorectal cancer risk per 400 g/
day increased intake, [7] but indicated that evidence for individual
products was lacking and/or uncertain.
Although an inverse association between consumption of total
milk with colorectal cancer risk has been consistently observed,
[7,8] whether the fat content of milk offsets a potential anti-
carcinogenic role is unclear. Animal models have shown that high-
fat consumption results in bile acid production, which in turn
promotes colorectal cancer, [9] but associations between milk
subtypes, with different fat contents, and colorectal cancer have
rarely been examined in prospective studies [10]. Similarly, how
other high-fat dairy products, such as cheese and yoghurt, are
associated with colorectal cancer risk is unclear, as mixed results
have been reported from the handful of previous prospective
studies. For cheese consumption, four prospective studies reported
null associations [8,11–13] and one study reported an inverse
association [14]. For yoghurt, three cohort studies have not found
any association, [8,11,12] but a recent analysis within the
European Prospective Investigation into Cancer and Nutrition
(EPIC)-Italy cohorts reported reduced risks amongst those with
higher consumption, even after adjustment for calcium intake
[15].
The principal anti-carcinogenic component contained within
dairy products is believed to be calcium. Most, [8,11,12,16,17] but
not all [18] cohort studies that have investigated calcium intake in
relation to colorectal cancer have reported inverse associations.
Previously within EPIC, a nested case-control study based on
1,248 colorectal cancer cases reported higher intakes of dietary
calcium were associated with lower colorectal cancer risk [19].
Although, whether this association differed according to dairy and
non-dairy sources of calcium was not investigated, nor was a
potential non-linear relationship that has been observed in other
cohorts [8,11].
In this present analysis, we investigated how intakes of milk with
different fat content (total, whole-fat, semi-skimmed, and
skimmed), cheese, yoghurt, and dietary calcium (total, dairy and
non-dairy sources) relate to colorectal cancer risk in the EPIC
study. The EPIC is a large prospective cohort from 10 European
countries with a wide range of dietary intakes. The large number
of participants and colorectal cancer cases accrued provided high
statistical power to investigate relationships according to individual
dairy products and across cancer sub-sites.
Methods
Outline
EPIC is an on-going multicentre prospective cohort study
designed to investigate the associations between diet, lifestyle,
genetic and environmental factors and various types of cancer. A
detailed description of the methods has previously been published
[20,21]. In summary, 521,448 participants (,70% women) mostly
aged 35 years or above were recruited between 1992 and 2000.
Participants were recruited from 23 study centres in ten European
countries: Denmark, France, Germany, Greece, Italy, the Nether-
lands, Norway, Spain, Sweden, and United Kingdom (UK).
Participants were recruited from the general population, with the
following exceptions: the French cohort were teacher health
insurance programme members; the Italian and Spanish cohorts
included members of blood donor associations and the general
population; the Utrecht (the Netherlands) and Florence (Italy)
cohorts contained participants from mammographic screening
programs; the Oxford (UK) cohort included a large proportion of
vegetarians, vegans, and low meat eaters; finally, only women
participated in the cohorts of France, Norway, Naples (Italy) and
Utrecht (the Netherlands). Written informed consent was provided
by all study participants. Ethical approval for the EPIC study was
obtained from the review boards of the International Agency for
Research on Cancer (IARC) and local participating centres.
Exclusions prior to the onset of the analyses included: participants
with prevalent cancer at enrolment (n=28,283); participants with
missing dietary, lifestyle, and anthropometric data (n=6,253);
participants in the highest and lowest 1% of the distribution for the
ratio between energy intake to estimated energy requirement
(n=9,600); and finally participants with extreme total dairy
Dairy Products and Colorectal Cancer
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477,122 participants (334,981 women and 142,141 men).
Diet and lifestyle questionnaires
Dietary information over the previous 12 months was obtained
at study baseline using validated country/centre specific dietary
questionnaires. In Malmo ¨ (Sweden), a dietary questionnaire was
combined with a 7-day food registration and interview. In Greece,
two Italian centres, and Spain, interviewers administered the
dietary questionnaires. In all other centres/countries, the ques-
tionnaires were self-administered. In Spain, France, and Ragusa
(Italy) questions were structured by meals, while in other countries
the structure was by food groups. Also at baseline, standardized
computer-based single 24-hour dietary recalls (24-hdr) were
collected from 36,994 study participants. This additional dietary
assessment was used to calibrate for differences in questionnaires
across countries [22]. Individual dairy products were categorized
as milk, cheeses, and yoghurts. Due to relatively low intakes and
incomplete measurements across centres, other individual dairy
products such as ice cream, cream desserts and milk-based
puddings, milk beverages, dairy creams and creamers for milk and
coffee were not analysed individually. Total milk was assessed as
the sum of all types of milk consumed (whole-fat, skimmed, semi
skimmed, and not specified). Semi-skimmed milk was defined as
milk containing 0.5–2.5% fat, and skimmed milk was defined as
having ,0.5% fat content. Milk subtype information was
unavailable in Norway, and only partially available in Germany,
Greece (both whole-fat milk only), and three Italian centres
(Florence, Varese, Turin; whole-fat and semi-skimmed milks only).
Cheese included all kinds of fresh, fermented, and matured cheese.
Yoghurt included natural and flavoured in all cohorts, and
additionally fermented milk in Sweden, Norway, and Denmark.
Intakes of calcium were obtained from the EPIC Nutrient Data
Base (ENDB); in which the nutritional composition of foods across
the different countries has been standardized [23].
Lifestyle questionnaires were used to obtain information on
education (used as a proxy for socioeconomic status), smoking
status and intensity, alcohol consumption, and physical activity
levels. Height and weight were measured at the baseline
examination in all centres apart from part of Oxford, and all of
the Norway and France sub-cohorts, where measurements were
self-reported via the lifestyle questionnaire [20].
Ascertainment of colorectal cancer incidence
Population cancer registries were used in Denmark, Italy, the
Netherlands, Norway, Spain, Sweden and the United Kingdom to
identify incident cancer diagnoses. In France, Germany and
Greece cancer cases during follow-up were identified by a
combination of methods including: health insurance records,
cancer and pathology registries, and by active follow-up directly
through study participants or through next-of-kin. Complete
follow-up censoring dates varied amongst centres, ranging
between 2005 and 2010.
Cancer incidence data were coded using the 10
th Revision of the
International Classification of Diseases (ICD-10) and the second
revision of the International Classification of Disease for Oncology
(ICDO-2). Proximal colon cancer included those within the
caecum, appendix, ascending colon, hepatic flexure, transverse
colon, and splenic flexure (C18.0–18.5). Distal colon cancer
included those within the descending (C18.6) and sigmoid (C18.7)
colon. Overlapping (C18.8) and unspecified (C18.9) lesions of the
colon were grouped among colon cancers only. Cancer of the
rectum included cancer occurring at the recto sigmoid junction
(C19) and rectum (C20).
Statistical analysis
Hazard ratios (HRs) and 95% confidence intervals (CIs) were
estimated using Cox proportional hazards models. Age was the
primary time variable in all models. Time at entry was age at
recruitment. Exit time was age at whichever of the following came
first: colorectal cancer diagnosis, death, or the last date at which
follow-up was considered complete in each centre. To control for
differing follow-up procedures, questionnaire design, and other
differences across centres, models were stratified by study centre.
Models were also stratified by sex and age at recruitment in 1-year
categories. Possible non-proportionality was assessed using an
analysis of Schoenfeld residuals, [24] with no evidence of non-
proportionality being detected.
Dietary intakes were modelled using either quintiles defined
across cohort participants (total milk, total dairy and calcium); pre-
defined categories (whole-fat, semi-skimmed, and skimmed milks:
non consumers, ,100, 100–199, 200–299, $300 g/day); and a
predefined low intake reference category and quartiles defined
across the remaining participants (cheese reference category
=,5 g/day; yoghurt reference category = non-consumers).
Intakes were also modelled as continuous variables, with HR
expressed per increments of: 200 g/day for milk; 100 g/day for
yoghurt; 50 g/day for cheese; 400 g/day for total dairy intake,
and 200 mg/day for calcium. Trend tests across intake categories
were calculated by assigning the median value of each intake
quintile/category and modelling as continuous terms into Cox
regression models.
Analyses for colorectal, colon, proximal colon, distal colon, and
rectal cancers were conducted for both sexes combined as no
interactions by sex were observed for intakes of total dairy
products (P=0.26), milk (P=0.28), cheese (P=0.58), yoghurt
(P=0.51), and dietary calcium (P=0.11). The results by sex are in
Tables S1, S2, S3, and S4 in File S1. All models were adjusted for
total energy intake, using the standard model, to obtain isocaloric
risk estimates and partly control for measurement error of dairy
products and calcium intake estimates. All models were addition-
ally adjusted for: body mass index (BMI; kg/m
2; continuous);
physical activity (inactive, moderately inactive, moderately active,
active, or missing); smoking status and intensity (never; current, 1–
15 cigarettes per day; current, 16–25 cigarettes per day; current,
25+ cigarettes per day; former, quit #10 years; former, quit 11–
20 years; former, quit 20+ years; current, pipe/cigar/occasional;
current/former, missing; or unknown); education level (none/
primary school completed, technical/professional school, second-
ary school, longer education – including university, or unknown);
menopausal status (premenopausal, postmenopausal, perimeno-
pausal/unknown menopausal status, or surgical postmenopausal);
ever use of oral contraceptive (yes, no, or unknown); ever use of
menopausal hormone therapy (yes, no, or unknown); and intakes
of alcohol (yes or no; continuous, g/day), red and processed meats,
and fibre (both continuous, g/day). Finer adjustment for body
shape was attempted by also controlling for waist circumference in
a subset of the cohort for which measurements were available.
When included in the multivariable models, instead of, or with
BMI, the risk estimates were virtually unchanged; and accordingly,
we adjusted solely for BMI. In the analyses for whole-fat, semi-
skimmed, and skimmed milk, the models included the covariates
as detailed above, plus additional adjustment for the other milk
subtypes. Similarly, the dairy and non-dairy calcium analyses were
mutually adjusted for one another.
To determine whether the dietary calcium-colorectal cancer
association differed according to anthropometric, lifestyle,
and dietary characteristics, we included interaction terms (multi-
plicative scale) in separate models. The statistical significance of
Dairy Products and Colorectal Cancer
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test.
Cox proportional hazard restricted cubic spline models were
used to explore possible deviation from a non-linear calcium-
colorectal cancer relationship, with five knots specified at the
median of each quintile of intake [25]. Heterogeneity of
associations across anatomical cancer sub-sites was assessed by
calculating x
2 statistics. The heterogeneity across countries was
explored by taking a meta-analytic approach [26]. To evaluate
possible reverse causality, cases diagnosed within the first 2 and
5 years of follow-up were excluded from the analyses.
To improve comparability of data across study centres and to
partially correct the relative risk estimates for the measurement
error of dietary intakes, a linear regression calibration model was
used utilizing the 24-hdr taken at baseline from a subset of the
cohort (n=34,426 in this analysis) [27,28]. The 24-hdr were
regressed on dietary questionnaire values, with adjustment for the
same list of covariates detailed above, and further control for the
week day and season of recall measurements. Country and sex-
specific calibration models were used to obtain individual
calibrated values of dietary exposure for all participants. Cox
proportional hazards regression models were then applied using
the calibrated values for each participant on a continuous scale.
The standard error of the de-attenuated coefficients was corrected
through bootstrap sampling. The P-value for the trend of the de-
attenuated coefficients was calculated by dividing the de-attenu-
ated coefficient by the bootstrap-derived standard error and
approximating the standardized normal distribution. (29).
Statistical tests used in the analysis were all two-sided and a P-
value of ,0.05 was considered statistically significant. Analyses
were conducted using SAS version 9.1 and Stata version 11.0.
Results
After a mean (SD) follow-up of 11.0 (2.8) years, 4,513 colorectal
cancer cases were documented amongst the 477,122 participants.
Of the 4,513 colorectal cancer cases, 2,868 were colon tumours
(1,298 proximal; 1,266 distal and 304 overlapping or unspecified),
and 1,645 were rectal tumours. The total person-years and
distribution of colorectal cancer cases by country are shown in
Table 1. The crude colorectal cancer incidence rates for men and
women were 12 and 7 cases per 10,000 person-years respectively.
Intakes of total dairy products were relatively low in Greece and
Germany and higher in Spain, the Netherlands, and Sweden
(men) cohorts. The lowest calcium intakes were reported in the
Italian cohort, with the highest in the Netherlands, UK (men), and
Germany (women). A higher proportion of current smokers were
observed amongst men and women in the lowest intake quintiles of
dairy products; whilst a greater proportion of physically active
participants were observed amongst men and women in the
highest intake quintiles (Table 2). Compared to those in the lower
intake quintiles, men and women with higher reported dairy
intakes tended to have lower BMIs, higher education level, and
reported lower intakes of alcohol, and higher intakes of dietary
fibre (Table 2).
Total milk and milk subtypes by fat content
Total milk was similarly inversely related to the cancer risk
across all locations of the bowel (colon vs. rectal P Heterogeneity
=0.83; distal colon vs. proximal colon P Heterogeneity =0.76)
(Table 3). In calibrated models, colorectal cancer risk was 7%
lower for each 200 g/day higher intake of total milk. Over 17% of
participants reported consuming more than one milk subtype. The
linear inverse associations for colorectal, colon, and rectal cancers
were of similar strength for whole-fat and skimmed milk, but there
were no significant associations for semi-skimmed milk (Table 4).
However, in sensitivity analyses, when the models included only
sole consumers of each milk subtype, identical inverse colorectal
cancer risk estimates were observed for whole-fat (HR per 200 g/
day 0.87, 95% CI: 0.79–0.95), semi-skimmed (HR per 200 g/day
0.87, 95% CI: 0.78–0.97) and skimmed milks (HR per 200 g/day
0.87, 95% CI: 0.76–0.99) (data not tabulated).
Cheese
Cheese consumption was inversely associated with colorectal
cancer in the categorical model (Table 3). The association
was significant for colon ($56 g/day vs. ,5 g/day HR, 0.83,
95% CI: 0.71–0.97; P-trend =0.047) but not rectal cancer,
although this difference was not significant (P Heterogeneity
=0.39). In the linear calibrated models, non-significant inverse
associations were observed for colorectal, colon and rectal
Table 1. Descriptive information of the European Prospective Investigation into Cancer and Nutrition participant countries.
Number of
participants Total person-years
Number of colorectal
cancer cases
Total dairy products
intake (g/day) *
Dietary calcium
intake (mg/day) *
Country Men Women Men Women Men Women Men Women Men Women
Denmark 26,266 28,699 284,431 316,511 474 353 246.1 215 967.8 875.8
France – 67,372 – 699,221 – 423 – 238.5 – 841.8
Germany 21,135 27,386 208,164 271,857 263 172 143.1 167.5 867.1 879.7
Greece 10,807 15,225 99,108 148,604 61 44 142.4 142.7 933.7 762.3
Italy 14,029 30,510 158,917 341,469 173 245 160.9 180 829.6 683.8
Norway – 35,169 – 342,279 – 210 – 215.8 – 745.7
Spain 15,147 24,849 182,950 299,557 185 144 289.4 364 946.5 886
Sweden 22,287 26,374 289,320 349,295 339 313 327.6 287 945.5 833.7
The Netherlands 9,618 26,854 115,334 315,529 81 305 281.5 342.4 1004.1 970.9
United Kingdom 22,852 52,543 252,096 586,301 324 404 288.8 288.7 1035.8 846.5
All EPIC 142,141 334,981 1,590,320 3,670,621 1,900 2,613 238.9 245.6 932.3 836.3
*Data are median intake information collected from 24-hour dietary recalls (n=34,426 participants).
doi:10.1371/journal.pone.0072715.t001
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(.56 g/day) had a 27% (95% CI: 0.58–0.93) reduced risk
compared to those consuming ,5 g/day, but in the calibrated
model, this association was not significant. No association was
observed for tumours in the distal region of the colon, and the
heterogeneity in association by colonic region was not statistically
significant (P Heterogeneity =0.82).
Table 2. Baseline characteristics of study participants by categories of total dairy intake.
Characteristic Quintile of total dairy intake
Q1 Q2 Q3 Q4 Q5
Dairy intake range (g/day) ,134 134–228 229–332 333–489 $490
Men
N 33,251 25,578 26,580 24,183 32,549
Colorectal cancer cases 484 325 343 330 418
Age at recruitment (years) 1 52.1 9.2 52.0 9.5 52.6 9.7 52.4 10.9 51.9 11.2
Body mass index (kg/m2) 26.8 3.8 26.8 3.6 26.5 3.6 26.2 3.5 26.1 3.6
Education `
Longer education including
University
24.7 26.8 26.5 28.7 26.3
Smoking status and intensity `
Current (%) 34.0 29.7 29.3 24.8 27.9
Physical activity `
Active (%) 22.7 22.4 23.9 23.5 27.8
Total energy intake (kcal/day) 2233 628 2331 648 2391 641 2457 648 2629 665
Red and processed meat intake
(g/day)
100.5 64.2 98.4 60.9 98.4 58.5 90.6 59.5 97.4 61.5
Calcium intake (mg/day) 685 232 871 272 991 286 1153 301 1496 398
Fibre intake (g/day) 23.2 8.5 23.7 8.0 24.3 8.1 24.8 8.2 25.4 8.7
Alcohol intake (g/day) 26.7 27.4 22.2 23.2 20.4 21.9 16.8 19.3 14.7 19.0
Women
N 62,174 69,846 68,845 71,241 62,875
Colorectal cancer cases 494 525 528 523 543
Age at recruitment (years) 1 50.4 9.5 50.3 9.3 50.9 9.5 50.9 10.3 51.6 10.4
Body mass index (kg/m2) 25.1 4.6 24.9 4.5 25 4.4 24.9 4.3 24.9 4.3
Education `
Longer education including
University
19.6 22.9 22.8 24.5 23.0
Smoking status and intensity `
Current (%) 24.5 20.2 18.0 16.6 18.6
Physical activity `
Active (%) 10.7 11.1 13.3 14.7 20.1
Ever use of contraceptive pill `
Yes (%) 56.1 57.7 56.4 58.0 57.9
Ever use of menopausal hormone therapy `
Yes (%) 22.9 24.2 24.5 24.0 25.7
Menopausal status `
Postmenopausal (%) 41.8 40.6 43.3 43.7 47.8
Total energy intake (kcal/day) 1694 485 1834 507 1941 521 2007 527 2176 539
Red and processed meat intake
(g/day)
62.8 42.3 65.7 41.6 66.6 41.6 64.3 42.9 66.3 44.0
Calcium intake (mg/day) 610 211 783 229 935 253 1094 292 1443 405
Fibre intake (g/day) 20.7 7.5 21.2 6.8 22.1 7.0 22.7 7.3 24.0 7.7
Alcohol intake (g/day) 8.7 13.2 8.3 11.9 8.2 11.6 7.4 10.6 7.0 10.4
Mean and standard deviation unless stated otherwise.
doi:10.1371/journal.pone.0072715.t002
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BOTH SEXES Basic model Multivariable models
Colon cancer
Food group (g/day)
CRC
cases
(n) *
Person-
years
Colorectal
cancer {
Colorectal
cancer ` All colon ` Proximal ` Distal ` Rectal cancer `
(n=4,513) (n=4,513) (n=2,868) (n=1,298) (n=1,266) (n=1,645)
Total milk
Q1 ,9 808 1,013,915 1.00 1.00 1.00 1.00 1.00 1.00
Q2 9–89 935 1,044,757 0.97 (0.88–
1.07)
0.97 (0.88–
1.07)
0.94 (0.83–
1.07)
0.91 (0.75–
1.10)
0.98 (0.82–
1.18)
1.02 (0.87–1.20)
Q3 90–187 836 1,037,641 0.92 (0.83–
1.02)
0.92 (0.83–
1.02)
0.95 (0.84–
1.08)
0.95 (0.78–
1.14)
0.93 (0.77–
1.13)
0.88 (0.74–1.04)
Q4 188–324 988 1,079,981 0.89 (0.80–
0.98)
0.90 (0.81–
0.99)
0.90 (0.79–
1.02)
0.88 (0.73–
1.07)
0.94 (0.77–
1.13)
0.91 (0.76–1.08)
Q5 $325 946 1,084,647 0.80 (0.72–
0.89)
0.81 (0.73–
0.90)
0.80 (0.70–
0.91)
0.84 (0.69–
1.02)
0.78 (0.63–
0.96)
0.84 (0.70–0.99)
P-trend ,0.001 ,0.001 0.001 0.11 0.009 0.017
Per 200 g/day – uncalibrated 0.94 (0.91–
0.97)
0.93 (0.90–
0.97)
0.95 (0.89–
1.01)
0.94 (0.88–
0.99)
0.95 (0.90–1.00)
Per 200 g/day – calibrated 0.93 (0.89–
0.98)
0.93 (0.88–
0.98)
0.93 (0.87–
0.99)
0.95 (0.87–
1.04)
0.94 (0.87–1.02)
Cheese
,5 495 506,354 1.00 1.00 1.00 1.00 1.00 1.00
Q1 5–18 1073 1,218,699 0.93 (0.83–
1.04)
0.92 (0.82–
1.03)
0.87 (0.76–
1.00)
0.76 (0.62–
0.92)
1.06 (0.85–
1.31)
1.01 (0.84–1.22)
Q2 19–32 1114 1,173,780 0.99 (0.88–
1.11)
0.99 (0.88–
1.11)
0.94 (0.81–
1.08)
0.84 (0.68–
1.03)
1.02 (0.81–
1.27)
1.10 (0.91–1.34)
Q3 33–55 980 1,185,851 0.88 (0.78–
0.99)
0.89 (0.79–
1.00)
0.86 (0.74–
0.99)
0.70 (0.56–
0.87)
1.01 (0.80–
1.26)
0.95 (0.78–1.16)
Q4 $56 851 1,176,256 0.86 (0.76–
0.98)
0.87 (0.76–
0.99)
0.83 (0.71–
0.97)
0.73 (0.58–
0.93)
0.91 (0.71–
1.17)
0.95 (0.76–1.18)
P–trend 0.009 0.02 0.047 0.054 0.2 0.23
Per 50 g/day – uncalibrated 0.95 (0.90–
1.00)
0.94 (0.88–
1.01)
0.90 (0.81–
1.01)
0.95 (0.85–
1.06)
0.96 (0.87–1.05)
Per 50 g/day – calibrated 0.92 (0.80–
1.06)
0.88 (0.75–
1.04)
0.85 (0.68–
1.05)
0.82 (0.66–
1.03)
1.00 (0.79–1.26)
Yoghurt
0 1074 1,060,510 1.00 1.00 1.00 1.00 1.00 1.00
Q1 ,17.8 958 1,051,433 0.96 (0.87–
1.07)
0.97 (0.88–
1.07)
0.98 (0.86–
1.11)
1.02 (0.84–
1.23)
0.93 (0.77–
1.12)
0.96 (0.81–1.13)
Q2 17.9–53 768 1,031,493 0.91 (0.82–
1.00)
0.93 (0.84–
1.03)
0.98 (0.86–
1.11)
0.96 (0.80–
1.17)
0.97 (0.80–
1.17)
0.86 (0.72–1.02)
Q3 54–108 824 1,047,993 0.88 (0.80–
0.98)
0.92 (0.83–
1.02)
0.98 (0.86–
1.10)
1.00 (0.83–
1.20)
0.95 (0.79–
1.14)
0.82 (0.69–0.97)
Q4 $109 889 1,069,512 0.86 (0.78–
0.95)
0.90 (0.81–
0.99)
0.88 (0.77–
1.00)
0.94 (0.79–
1.13)
0.84 (0.69–
1.02)
0.93 (0.79–1.10)
P–trend 0.002 0.043 0.037 0.44 0.09 0.55
Per 100 g/day – calibrated 0.99 (0.95–
1.03)
0.99 (0.94–
1.04)
1.00 (0.94–
1.07)
0.98 (0.91–
1.05)
0.99 (0.93–1.05)
Per 100 g/day – uncalibrated 0.97 (0.90–
1.04)
0.98 (0.90–
1.06)
1.02 (0.92–
1.15)
0.93 (0.82–
1.06)
0.96 (0.85–1.09)
Total dairy
Q1 ,134 978 1,028,047 1.00 1.00 1.00 1.00 1.00 1.00
Q2 134–228 850 1,031,665 0.89 (0.81–
0.97)
0.90 (0.82–
0.99)
0.86 (0.77–
0.97)
0.75 (0.62–
0.90)
0.91 (0.76–
1.08)
0.97 (0.83–1.13)
Q3 229–332 871 1,053,198 0.83 (0.75–
0.91)
0.85 (0.77–
0.93)
0.86 (0.76–
0.96)
0.81 (0.68–
0.97)
0.86 (0.72–
1.02)
0.83 (0.71–0.97)
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Yoghurt intake was significantly inversely related to colorectal
cancer risk in categorical models ($109 g/day vs. non-consumers,
HR 0.90, 95% CI: 0.81–0.99; P-trend =0.043) (Table 3). The
inverse association was restricted to the colon and not observed for
tumours in the rectum, although the difference was not statistically
significant (P Heterogeneity =0.79). Within the colon the
difference in association across the distal and proximal regions
was non-significant (P Heterogeneity =0.29). No associations were
observed in the linear calibrated models for cancers across all
bowel locations. After adjustment for dietary calcium intake the
inverse association for colorectal cancer using the categorical
model was no longer significant ($109 g/day vs. non-consumers,
HR 0.94, 95% CI: 0.85–1.04; P-trend =0.33; data not tabulated).
Total dairy intake
Total dairy intake was significantly inversely associated to
colorectal cancer risk ($490 g/day vs. ,134 g/day, HR 0.77,
95% CI: 0.70–0.86; P-trend ,0.001) (Table 3). In calibrated
models, each 400 g/day higher intake of total dairy products was
associated with a 14% lower risk. The inverse association was of
similar magnitude for colon and rectal cancer (P Heterogeneity
=.72); and within the colon, there no evidence of heterogeneity
across distal and proximal regions (P Heterogeneity =0.66).
Dietary calcium
For dietary calcium, similar strength inverse associations were
observed across all locations of the colorectum (colon vs. rectal P
Heterogeneity =0.56; distal colon vs. proximal colon P Hetero-
geneity =1.00) (Table 5). There was no deviation from linearity
for the relationship between dietary calcium and colorectal cancer
in the restricted cubic spline model (P=0.43) (data not shown).
Calcium intake from dairy foods was inversely associated to cancer
risk across all locations of the bowel. When calcium and milk were
included in the same models, the inverse associations for milk
weakened and became non-significant, but the significant inverse
associations for calcium remained (data not shown). Dietary
calcium from non-dairy sources was not inversely associated with
colorectal cancer risk. The association between dietary calcium
intake and risk of colorectal cancer did not differ by BMI
(P=0.56), waist circumference (men P=0.74; women P=0.64),
physical activity (P=0.26), smoking status (P=0.37 alcohol
consumption (P=0.75), and intakes of red and processed meat
(P=0.50), and fibre (P=0.65) (data not tabulated).
Between country heterogeneity and inclusion of
preclinical disease
There was evidence of significant heterogeneity by country for
total dairy products (P=0.034) (Figure S1 in File S1); although
risk estimates #1 were observed in most countries. No associations
were observed in the Sweden and Denmark cohorts. Non-
significant between country heterogeneity was observed for intakes
of dietary calcium (P=0.60; Figure S2 in File S1), total milk
(P=0.13), cheese (P=0.64), and yoghurt (P=0.12).
Excluding the participants with less than 2 and 5 years of
follow-up (including 502 and 1,483 colorectal cancer cases
respectively) from the total dairy, total milk, cheese, yoghurt,
and calcium intake analyses resulted in negligible differences in the
colorectal cancer associations (data not shown).
Discussion
In this analysis of the EPIC cohort, after a mean follow-up of
11 years where 4,513 cases accrued, higher intakes of all subtypes
of milk, cheese, yoghurt, total dairy products and dietary calcium
from dairy sources were associated with reduced colorectal cancer
risk. Overall, our results provided no evidence for divergent
Table 3. Cont.
BOTH SEXES Basic model Multivariable models
Colon cancer
Food group (g/day)
CRC
cases
(n) *
Person-
years
Colorectal
cancer {
Colorectal
cancer ` All colon ` Proximal ` Distal ` Rectal cancer `
(n=4,513) (n=4,513) (n=2,868) (n=1,298) (n=1,266) (n=1,645)
Q4 333–489 853 1,065,426 0.76 (0.69–
0.84)
0.79 (0.71–
0.87)
0.78 (0.69–
0.88)
0.81 (0.68–
0.98)
0.74 (0.61–
0.89)
0.80 (0.67–0.94)
Q5 $490 961 1,082,605 0.75 (0.68–
0.83)
0.77 (0.70–
0.86)
0.75 (0.66–
0.86)
0.75 (0.62–
0.91)
0.74 (0.61–
0.90)
0.81 (0.69–0.96)
P-trend ,0.001 ,0.001 ,0.001 0.04 0.001 0.008
Per 400 g/day – uncalibrated 0.88 (0.83–
0.93)
0.87 (0.80–
0.93)
0.90 (0.81–
1.01)
0.86 (0.77–
0.96)
0.90 (0.82–0.99)
Per 400 g/day – calibrated 0.86 (0.79–
0.94)
0.85 (0.76–
0.95)
0.89 (0.78–
1.03)
0.85 (0.73–
0.99)
0.88 (0.76–1.02)
{Basic model – Cox regression using total energy intake (continuous), and stratified by age (1-year categories), sex, and centre.
`Multivariable model – Cox regression using total energy intake (continuous), body mass index (continuous), physical activity index (inactive, moderately inactive,
moderately active, active, or missing), smoking status and intensity (never; current, 1–15 cigarettes per day; current, 16–25 cigarettes per day; current, 16+ cigarettes per
day; former, quit #10 years; former, quit 11–20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown), education status (none,
primary school completed, technical/professional school, secondary school, longer education including university, or not specified), ever use of contraceptive pill (yes,
no, or unknown), ever use of menopausal hormone therapy (yes, no, or unknown), menopausal status (premenopausal, postmenopausal, perimenopausal/unknown
menopausal status, or surgical postmenopausal), alcohol consumption (yes or no; and continuous) and intakes of red and processed meat and fibre (both continuous),
and stratified by age (1-year categories), sex, and centre.
*Total number of colorectal cancer cases across intake categories.
doi:10.1371/journal.pone.0072715.t003
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cancer risk.
The inverse association we observed for total milk consumption
was similar to what was reported by both the Pooling Project of
cohort studies, and a recent systematic review [7,8]. Few
prospective studies have previously investigated the associations
for milk by fat content. In the Adventist Health Study, a stronger
inverse association was reported for non-fat milk consumers
compared to consumers of milks containing higher fat [10]. In our
larger analysis, similar strength inverse associations were observed
for all milk subtypes, refuting the notion that the milk-colorectal
cancer association differs according to fat content, at least in the
range of intakes recorded within EPIC.
The inverse cheese-colorectal cancer association observed in the
categorical models provides further evidence that the fat content of
dairy products does not impair any possible anti-carcinogenic role.
However, this inverse association was not replicated in the linear
calibrated model, where a non-significant lower risk was yielded.
Table 4. Multivariable hazard ratios (95% confidence intervals) of colorectal cancer risk by milk subtype by fat content
consumption categories.
BOTH SEXES Basic model
Multivariable
model Multivariable models
Colon cancer
Milk subtype
(g/day)
CRC
cases (n) *
Person-
years
Colorectal
cancer {
Colorectal
cancer ` All colon ` Proximal ` Distal `
Rectal
cancer `
Whole-fat milk Q
0 1397 1,624,243 1.00 1.00 1.00 1.00 1.00 1.00
,100 2256 2,530,622 1.02 (0.92–1.13) 1.03 (0.93–1.13) 1.03 (0.91–1.17) 1.09 (0.90–1.31) 1.05 (0.87–1.26) 1.02 (0.86–1.21)
100–199 259 326,905 1.00 (0.87–1.16) 0.98 (0.85–1.13) 1.02 (0.85–1.22) 1.16 (0.89–1.52) 0.98 (0.75–1.28) 0.91 (0.71–1.18)
200–299 196 219,597 0.96 (0.81–1.12) 0.92 (0.78–1.08) 0.93 (0.76–1.14) 0.97 (0.71–1.32) 0.88 (0.65–1.21) 0.89 (0.67–1.18)
$300 195 217,295 0.90 (0.77–1.06) 0.86 (0.72–1.02) 0.83 (0.67–1.03) 0.92 (0.68–1.26) 0.82 (0.59–1.14) 0.90 (0.68–1.20)
P-trend 0.11 0.02 0.048 0.42 0.10 0.21
Per 200 g/day – uncalibrated 0.93 (0.88–0.98) 0.92 (0.86–0.99) 0.94 (0.85–1.04) 0.92 (0.82–1.02) 0.94 (0.85–1.03)
Per 200 g/day – calibrated 0.90 (0.82–0.99) 0.91 (0.82–1.02) 0.90 (0.79–1.03) 0.95 (0.81–1.11) 0.89 (0.76–1.04)
Semi-skimmed milk"
0 1611 1,915,967 1.00 1.00 1.00 1.00 1.00 1.00
,100 1015 999,256 0.94 (0.84–1.04) 0.92 (0.82–1.02) 0.88 (0.77–1.01) 0.93 (0.76–1.14) 0.86 (0.70–1.05) 0.97 (0.81–1.16)
100–199 396 478,349 0.98 (0.87–1.10) 0.93 (0.82–1.05) 0.94 (0.81–1.09) 0.94 (0.75–1.17) 0.88 (0.70–1.10) 0.91 (0.74–1.12)
200–299 375 390,635 0.98 (0.87–1.11) 0.92 (0.81–1.05) 0.92 (0.79–1.07) 0.90 (0.71–1.13) 0.95 (0.76–1.20) 0.93 (0.76–1.15)
$300 366 406,723 0.92 (0.82–1.04) 0.85 (0.75–0.97) 0.84 (0.71–0.99) 0.97 (0.77–1.22) 0.73 (0.57–0.95) 0.87 (0.70–1.08)
P-trend 0.44 0.042 0.13 0.80 0.10 0.18
Per 200 g/day – uncalibrated 0.96 (0.92–1.01) 0.96 (0.91–1.01) 0.98 (0.90–1.06) 0.95 (0.87–1.03) 0.97 (0.91–1.04)
Per 200 g/day – calibrated 0.97 (0.91–1.05) 0.97 (0.90–1.05) 0.99 (0.90–1.10) 0.97 (0.87–1.09) 0.98 (0.88–1.10)
Skimmed milk 1
0 2290 2,548,660 1.00 1.00 1.00 1.00 1.00 1.00
,100 559 616,032 1.01 (0.90–1.13) 1.01 (0.90–1.14) 1.04 (0.90–1.20) 1.08 (0.87–1.34) 1.04 (0.84–1.29) 0.97 (0.80–1.18)
100–199 232 246,904 1.05 (0.91–1.20) 1.02 (0.89–1.18) 1.03 (0.86–1.22) 0.97 (0.74–1.27) 1.09 (0.84–1.41) 1.02 (0.81–1.28)
200–299 113 149,954 0.81 (0.67–0.98) 0.78 (0.64–0.95) 0.84 (0.66–1.06) 0.99 (0.72–1.37) 0.71 (0.47–1.05) 0.67 (0.47–0.96)
$300 216 250,916 0.81 (0.70–0.93) 0.78 (0.67–0.90) 0.72 (0.60–0.88) 0.68 (0.51–0.90) 0.79 (0.59–1.05) 0.87 (0.69–1.10)
P-trend 0.002 ,0.001 ,0.001 0.012 0.06 0.10
Per 200 g/day – uncalibrated 0.92 (0.87–0.97) 0.91 (0.85–0.97) 0.89 (0.81–0.98) 0.94 (0.85–1.04) 0.93 (0.86–1.01)
Per 200 g/day – calibrated 0.90 (0.79–1.02) 0.88 (0.78–0.99) 0.82 (0.72–0.94) 0.95 (0.83–1.10) 0.92 (0.81–1.06)
{Basic model – Cox regression using total energy intake (continuous), and stratified by age (1-year categories), sex, and centre.
`Multivariable model – Cox regression using total energy intake (continuous), body mass index (continuous), physical activity index (inactive, moderately inactive,
moderately active, active, or missing), smoking status and intensity (never; current, 1–15 cigarettes per day; current, 16–25 cigarettes per day; current, 16+ cigarettes per
day; former, quit #10 years; former, quit 11–20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown), education status (none,
primary school completed, technical/professional school, secondary school, longer education including university, or not specified), ever use of contraceptive pill (yes,
no, or unknown), ever use of menopausal hormone therapy (yes, no, or unknown), menopausal status (premenopausal, postmenopausal, perimenopausal/unknown
menopausal status, or surgical postmenopausal), alcohol consumption (yes or no; and continuous) and intakes of red and processed meat and fibre (both continuous),
and stratified by age (1-year categories), sex, and centre.
w Excluding Norway.
"Excluding Norway, Germany, and Greece.
1Excluding Norway, Germany, Greece, Florence (Italy), Varese (Italy), and Turin (Italy).
*Total number of colorectal cancer cases across intake categories.
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BOTH SEXES Basic model
Multivariable
model Multivariable models
Colon cancer
CRC
cases
(n) * Person-years
Colorectal
cancer {
Colorectal
cancer ` All colon ` Proximal ` Distal ` Rectal cancer `
(n=4,513) (n=4,513) (n=2,868) (n=1,298) (n=1,266) (n=1,645)
Calcium (mg/day)
Q1 ,661 943 1,034,125 1.00 1.00 1.00 1.00 1.00 1.00
Q2 662–845 885 1,048,337 0.87 (0.79–
0.95)
0.88 (0.80–0.97) 0.92 (0.82–
1.04)
0.94 (0.79–
1.12)
0.89 (0.74–1.06) 0.82 (0.70–0.96)
Q3 846–
1030
921 1,054,640 0.86 (0.78–
0.94)
0.89 (0.81–0.98) 0.90 (0.80–
1.02)
0.85 (0.71–
1.03)
0.96 (0.80–1.15) 0.87 (0.74–1.02)
Q4 1031–
1279
891 1,059,887 0.78 (0.70–
0.87)
0.82 (0.74–0.91) 0.81 (0.71–
0.93)
0.80 (0.66–
0.98)
0.76 (0.63–0.93) 0.83 (0.70–0.98)
Q5 $1280 873 1,063,951 0.73 (0.65–
0.82)
0.78 (0.69–0.88) 0.75 (0.65–
0.88)
0.77 (0.62–
0.97)
0.72 (0.58–0.91) 0.82 (0.67–0.99)
P-trend ,0.001 ,0.001 ,0.001 0.014 0.003 0.12
Per 200 mg/day – uncalibrated 0.95 (0.93–0.97) 0.95 (0.93–
0.98)
0.95 (0.91–
0.99)
0.96 (0.92–0.99) 0.96 (0.92–0.99)
Per 200 mg/day – calibrated 0.95 (0.91–0.99) 0.94 (0.90–
0.98)
0.94 (0.89–
0.99)
0.94 (0.88–0.99) 0.96 (0.91-1.02)
Dairy calcium (mg/day)
Q1 ,308 998 1,027,736 1.00 1.00 1.00 1.00 1.00 1.00
Q2 309–462 869 1,038,754 0.84 (0.77–
0.92)
0.85 (0.78–0.94) 0.86 (0.76–
0.96)
0.75 (0.63–
0.90)
0.99 (0.83–1.17) 0.85 (0.73–0.99)
Q3 463–621 866 1,049,098 0.81 (0.74–
0.89)
0.83 (0.76–0.91) 0.84 (0.74–
0.94)
0.85 (0.72–
1.02)
0.83 (0.69–0.99) 0.82 (0.70–0.97)
Q4 622–838 866 1,061,151 0.75 (0.68–
0.83)
0.78 (0.70–0.86) 0.78 (0.69–
0.88)
0.76 (0.63–
0.91)
0.78 (0.65–0.94) 0.78 (0.66–0.92)
Q5 $839 909 1,076,084 0.75 (0.68–
0.83)
0.78 (0.70–0.87) 0.75 (0.66–
0.86)
0.73 (0.60–
0.89)
0.78 (0.63–0.95) 0.83 (0.70–0.99)
P–trend ,0.001 ,0.001 ,0.001 0.009 0.003 0.053
Per 200 mg/day – uncalibrated 0.95 (0.93–0.97) 0.95 (0.92–
0.97)
0.95 (0.91–
0.98)
0.95 (0.92–0.99) 0.96 (0.92–0.99)
Per 200 mg/day – calibrated 0.95 (0.91–0.99) 0.94 (0.90–
0.99)
0.94 (0.89–
1.00)
0.94 (0.89–1.00) 0.96 (0.90–1.03)
Non–dairy calcium (mg/day)
Q1 ,276 816 1,060,798 1.00 1.00 1.00 1.00 1.00 1.00
Q2 277–344 971 1,061,241 1.07 (0.97–
1.19)
1.10 (0.99-1.22) 1.10 (0.96–
1.25)
1.07 (0.88–
1.31)
1.13 (0.93–1.37) 1.11 (0.93–1.32)
Q3 345–410 975 1,054,658 1.05 (0.94–
1.17)
1.09 (0.97–1.23) 1.12 (0.97–
1.29)
1.25 (1.01–
1.55)
1.03 (0.82–1.28) 1.05 (0.87–1.27)
Q4 411–501 891 1,044,603 0.96 (0.85–
1.09)
1.01 (0.89–1.16) 1.05 (0.89–
1.23)
1.04 (0.81–
1.33)
1.08 (0.85–1.38) 0.96 (0.77–1.20)
Q5 $502 855 1,031,522 0.98 (0.85–
1.12)
1.05 (0.90–1.23) 1.09 (0.89–
1.32)
1.18 (0.88–
1.59)
0.98 (0.72–1.32) 0.99 (0.76–1.29)
P–trend 0.244 0.87 0.77 0.45 0.64 0.52
Per 200 mg/day – uncalibrated 1.02 (0.94–1.10) 1.06 (0.96–
1.17)
1.05 (0.91–
1.21)
1.07 (0.92–1.25) 0.95 (0.83–1.08)
Per 200 mg/day – calibrated 1.00 (0.81–1.24) 1.06 (0.87–
1.30)
0.94 (0.76–
1.15)
1.15 (0.92–1.43) 0.92 (0.73–1.15)
{Basic model – Cox regression using total energy intake (continuous), and stratified by age (1-year categories), sex, and centre.
`Multivariable model – Cox regression using total energy intake (continuous), body mass index (continuous), physical activity index (inactive, moderately inactive,
moderately active, active, or missing), smoking status and intensity (never; current, 1–15 cigarettes per day; current, 16–25 cigarettes per day; current, 16+ cigarettes per
day; former, quit #10 years; former, quit 11–20 years; former, quit 20+ years; current, pipe/cigar/occasional; current/former, missing; unknown), education status (none,
primary school completed, technical/professional school, secondary school, longer education including university, or not specified), ever use of contraceptive pill (yes,
no, or unknown), ever use of menopausal hormone therapy (yes, no, or unknown), menopausal status (premenopausal, postmenopausal, perimenopausal/unknown
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have usually reported null results [11–13]. For yoghurt, an inverse
colorectal cancer association in the categorical model was also not
replicated in the linear calibrated model. Some evidence suggests
that lactic acid bacteria contained within yoghurt products may
protect against colorectal cancer [29]. Recently, an analysis of the
EPIC-Italy cohorts reported a 35% reduced colorectal cancer risk
- after adjustment for calcium intake – amongst participants who
consumed more than 25 g/day of yoghurt compared to non-
consumption (less than 1 g/day) [15]. When we additionally
adjusted for calcium intake, the inverse colorectal association in
the categorical model disappeared. However, our results do not
rule out the lactic acid hypothesis, as the types of yoghurt
consumed across EPIC countries may differ in lactic acid content,
and this information may not have been captured within our
study.
We observed consistent inverse associations across all cancer
sub-sites for dietary calcium intake, in line with the majority of
published cohort studies [8,11,12,16,17]. Some studies have
reported a threshold level for calcium intake (,1,000 to
,1,400 mg/day), above which reductions in colorectal cancer
risk are not observed [8,11]. In our analysis we did not observe a
threshold association at any level of intake, or any departure from
linearity. Our inverse associations were limited to dairy sources of
calcium, as we observed either null or weak non-statistically
significant associations in the non-dairy calcium models. Other
prospective studies have reported no association [18,30] or
increased risk [16] for non-dairy calcium intake with colorectal
and colon cancers. A possible explanation for the non-inverse
associations for non-dairy calcium could be that plant sources of
calcium – the main contributors to non-dairy calcium intake
amongst EPIC participants –contain oxalate and phytate which
have been shown to inhibit calcium absorption [31]. Across all
EPIC centres, milk contributes most to the consumption of total
dairy products [32]. Lactose and casein in milk may increase the
bioavailability of calcium, which could also explain the inverse
associations we observed for dairy calcium [33]. The primary anti-
carcinogenic component contained within dairy foods is believed
to be calcium [29]. Laboratory studies have shown that calcium
can induce apoptosis in colonic epithelium cells, [34] and alter
colonic K-ras gene mutations [35]. Animal and human interven-
tion studies have shown that calcium impacts upon colonic cell
differentiation: indirectly, by binding to available bile acids and
fatty acids, suppressing their ability to modify colonic cell
proliferation [36,37]; and directly, by suppressing colonic epithe-
lial cell proliferation and inducing terminal differentiation [38].
Evidence from clinical trials suggests that calcium supplementation
reduces the recurrence of colorectal adenoma [39]. Beyond the
calcium content of dairy products, other constituents contained
within these products may explain the inverse associations
observed. For instance lactoferrin, vitamin D in fortified dairy
products, and certain fatty acids, such as butyric acid, have been
linked with having possible beneficial roles against colorectal
cancer. [29] However, isolating the influence of individual food
components present simultaneously in the same foods is difficult.
The public health implications of our results are complicated by
the contrasting associations between calcium intake and prostate
cancer. Dietary calcium has been consistently associated with
increased prostate cancer risk, and the WCRF/AICR 2007 Expert
report judged it a ‘‘probable’’ cause of the disease [40]. Within
EPIC, a 300 mg/day intake of dietary calcium was previously
associated with a 9% increased risk of prostate cancer [41]. In our
analysis, an equivalent daily intake amongst men and women
would be associated with 7% statistically significant reduced
colorectal cancer risks. At present, the available evidence for the
divergent associations between cancer sites has not been consid-
ered convincing enough to justify potential sex-specific calcium
and dairy product intake recommendations.
Strengths of our study include its large-scale prospective design,
the large number of colorectal cancer cases and the possibility of
controlling for the main potential confounders. However, infor-
mation on past bowel cancer screening and previous endoscopy
procedures were unknown; although previous studies have
observed unchanged inverse calcium-colon cancer relationships
when the multivariable models were additionally adjusted for
endoscopy history [30]. A further limitation was that intake of
calcium supplements could not be included in our analysis;
although other large cohort studies have observed only minor
differences in associations between total calcium intakes (supple-
ments plus diet) compared solely to dietary sources [8,17]. In our
study, diet was assessed through dietary questionnaires, which are
subject to measurement error. Random misclassification may have
thus caused an attenuation of the estimates of the diet-disease
association; however, we partially corrected our estimates through
regression calibration using 24-hdr data [28]. Another study
limitation was that changes in diet during follow-up could not be
taken into account; however, this does not appear to have
influenced our conclusions since our results are consistent with
those of other cohort studies, some of which used cumulative
estimates of diet over time [8,30].
In conclusion, our study supports potential beneficial roles for
dietary intakes of dairy products and calcium on colorectal cancer
prevention. Inverse associations were observed for low-fat and
high-fat dairy products; indicating that the fat content contained
within dairy products does not influence this relationship.
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menopausal status, or surgical postmenopausal), alcohol consumption (yes or no; and continuous) and intakes of red and processed meat, fibre, and mutual adjustment
for other dietary calcium source (all continuous), and stratified by age (1-year categories), sex, and centre.
*Total number of colorectal cancer cases across intake categories.
doi:10.1371/journal.pone.0072715.t005
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File S1 Supporting information. Figure S1. Multivariable
hazard ratios and 95% confidence intervals of colorectal cancer
risk by country, per 400 g/day increase in total dairy intake.
Hazard ratios estimated by Cox proportional hazards models
adjusting for total energy intake (continuous), body mass index
(continuous), physical activity index (inactive, moderately inactive,
moderately active, active, or missing), smoking status and intensity
(never; current, 1–15 cigarettes per day; current, 16–25 cigarettes
per day; current, 16+ cigarettes per day; former, quit #10 years;
former, quit 11–20 years; former, quit 20+ years; current, pipe/
cigar/occasional; current/former, missing; unknown), education
status (none, primary school completed, technical/professional
school, secondary school, longer education including university, or
not specified), ever use of contraceptive pill (yes, no, or unknown),
ever use of menopausal hormone therapy (yes, no, or unknown),
menopausal status (premenopausal, postmenopausal, perimeno-
pausal/unknown menopausal status, or surgical postmenopausal),
alcohol consumption (yes or no; and continuous) and intakes of red
and processed meat and fibre (both continuous), and stratified by
age (1-year categories), sex, and centre. Figure S2. Multivariable
hazard ratios and 95% confidence intervals of colorectal cancer
risk by country, per 200 mg/day increase in total dietary calcium
(B). Hazard ratios estimated by Cox proportional hazards models
adjusting for total energy intake (continuous), body mass index
(continuous), physical activity index (inactive, moderately inactive,
moderately active, active, or missing), smoking status and intensity
(never; current, 1–15 cigarettes per day; current, 16–25 cigarettes
per day; current, 16+ cigarettes per day; former, quit #10 years;
former, quit 11–20 years; former, quit 20+ years; current, pipe/
cigar/occasional; current/former, missing; unknown), education
status (none, primary school completed, technical/professional
school, secondary school, longer education including university, or
not specified), ever use of contraceptive pill (yes, no, or unknown),
ever use of menopausal hormone therapy (yes, no, or unknown),
menopausal status (premenopausal, postmenopausal, perimeno-
pausal/unknown menopausal status, or surgical postmenopausal),
alcohol consumption (yes or no; and continuous) and intakes of red
and processed meat and fibre (both continuous), and stratified by
age (1-year categories), sex, and centre. Table S1. Multivariable
hazard ratios (95% confidence intervals) of colorectal cancer risk in
men by dairy product consumption categories. Table S2.
Multivariable hazard ratios (95% confidence intervals) of colorec-
tal cancer risk in women by dairy product consumption categories.
Table S3. Multivariable hazard ratios (95% confidence intervals)
of colorectal cancer risk in men by dietary calcium intake
categories. Table S4. Multivariable hazard ratios (95% confidence
intervals) of colorectal cancer risk in women by dietary calcium
intake categories.
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